Turnium Extends Exclusivity Period of Non-Binding Letter of Intent with Insentra

Vancouver, Canada–(Newsfile Corp. – December 29, 2025) – Turnium Technology Group Inc. (TSXV: TTGI) (FSE: E48) (“Turnium” or the “Company“), a global leader in Technology-as-a-Service (TaaS) and partner enablement services, provides an update regarding its previously announced non-binding letter of intent dated November 9, 2025 (the “LOI“) with Insentra Management Services Pty Ltd on behalf […]

DesignRush Releases List of Top Web Design Agencies as 91% of Users Face Online Service Issues

New York, New York–(Newsfile Corp. – December 29, 2025) – DesignRush, a leading B2B platform, released its December 2025 ranking of the top web design agencies that help businesses improve digital experiences and reduce user drop-off. Recent data from Conviva shows that 91% of consumers encountered frustrating digital service issues in the past year. These

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA(R) for the Treatment of Niemann-Pick Disease Type C (NPC)

(NASDAQ:ZVRA), CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar, an Ireland-based pharmaceutical services provider with a proven record

illumin Announces TSX Acceptance of Normal Course Issuer Bid

(TSX:ILLM),(OTC US:ILLMF),(Other OTC:ILLMF), TORONTO, Dec. 29, 2025 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM) (OTCQB:ILLMF) (“illumin” or the “Company“) is pleased to announce that it has received approval from the Toronto Stock Exchange (“TSX“) to renew its normal course issuer bid (“NCIB“). Under the NCIB, the Company may purchase for cancellation up to 3,858,045 common

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA(R) for the Treatment of Niemann-Pick Disease Type C (NPC)

Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA(R) for the Treatment of Niemann-Pick Disease Type C (NPC) GlobeNewswire December 29, 2025 CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced

illumin Announces TSX Acceptance of Normal Course Issuer Bid

illumin Announces TSX Acceptance of Normal Course Issuer Bid GlobeNewswire December 29, 2025 TORONTO, Dec. 29, 2025 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM) (OTCQB:ILLMF) (“illumin” or the “Company“) is pleased to announce that it has received approval from the Toronto Stock Exchange (“TSX“) to renew its normal course issuer bid (“NCIB“). Under the NCIB,

Canstar Concludes 2025 Field Season, Reports Year-in-Review Milestones, and Advances Winter Technical Program Toward 2026 Drilling

Toronto, Ontario–(Newsfile Corp. – December 29, 2025) – Canstar Resources Inc. (TSXV: ROX) (the “Company”) reports that its 2025 field season in Newfoundland has concluded and its Winter 2025/2026 technical program is now underway, with the objective of commencing exploration drilling at the start of the 2026 exploration season, subject to permitting and final program

Levi & Korsinsky Reminds Shareholders of an Investigation into AST SpaceMobile, Inc. (ASTS) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of AST SpaceMobile, Inc. ("AST SpaceMobile, Inc.") (NASDAQ:ASTS) concerning possible violations of federal securities laws. On December 15, 2025, it was revealed that AST’s launch of its BlueBird 6 was delayed. The launch,

Scroll to Top